197 related articles for article (PubMed ID: 32200137)
1. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors.
Roch B; Coffy A; Jean-Baptiste S; Palaysi E; Daures JP; Pujol JL; Bommart S
Lung Cancer; 2020 May; 143():19-26. PubMed ID: 32200137
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Takamori S; Takada K; Shimokawa M; Jinnnouchi M; Matsubara T; Haratake N; Miura N; Toyozawa R; Yamaguchi M; Takenoyama M; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
Cancer Immunol Immunother; 2021 Jun; 70(6):1745-1753. PubMed ID: 33389013
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of CT-determined sarcopenia in older patients with advanced squamous cell lung cancer treated with programmed death-1 inhibitors.
Ying L; Xu L; Yang J; Zhang Q
Sci Rep; 2024 May; 14(1):12025. PubMed ID: 38797769
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab.
Jo H; Yoshida T; Horinouchi H; Yagishita S; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Yamamoto N; Takahashi K; Motoi N; Ohe Y
Cancer Immunol Immunother; 2022 Feb; 71(2):387-398. PubMed ID: 34180007
[TBL] [Abstract][Full Text] [Related]
5. Survival and biomarkers for cachexia in non-small cell lung cancer receiving immune checkpoint inhibitors.
Murata D; Azuma K; Matsuo N; Murotani K; Matama G; Kawahara A; Sasada T; Tokito T; Hoshino T
Cancer Med; 2023 Oct; 12(19):19471-19479. PubMed ID: 37712645
[TBL] [Abstract][Full Text] [Related]
6. Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study.
Thuillier P; Joly C; Alavi Z; Crouzeix G; Descourt R; Quere G; Kerlan V; Roudaut N
Cancer Immunol Immunother; 2021 Jul; 70(7):2023-2033. PubMed ID: 33423089
[TBL] [Abstract][Full Text] [Related]
7. Non-small cell lung cancer and immune checkpoint inhibitor therapy: does non-alcoholic fatty liver disease have an effect?
Li Y; Gong B; Guo Y; Liu W; Chen C; Jiang S; Pan F; Song J; Yang L; Zhou G
BMC Cancer; 2024 Apr; 24(1):535. PubMed ID: 38671373
[TBL] [Abstract][Full Text] [Related]
8. Metformin use and lung cancer survival: a population-based study in Norway.
Brancher S; Støer NC; Weiderpass E; Damhuis RAM; Johannesen TB; Botteri E; Strand TE
Br J Cancer; 2021 Mar; 124(5):1018-1025. PubMed ID: 33262518
[TBL] [Abstract][Full Text] [Related]
9. Predictive impact of sarcopenia in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: A retrospective study.
Feng Y; Wang L; Guo F; Zhu F; Shi J; Wang Y; Zhang Y; Chen X; Zhang L
Heliyon; 2024 Mar; 10(5):e27282. PubMed ID: 38463845
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral density as an individual prognostic biomarker in NSCLC patients treated with immune checkpoint inhibitors.
Lou J; Gong B; Li Y; Guo Y; Li L; Wang J; Liu W; You Z; Zhang H; Pan F; Liang B; Yang L; Zhou G
Front Immunol; 2024; 15():1332303. PubMed ID: 38698843
[TBL] [Abstract][Full Text] [Related]
11. Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.
Liu M; Jin Q; Wang H; Li Y
Front Immunol; 2024; 15():1396927. PubMed ID: 38690276
[TBL] [Abstract][Full Text] [Related]
12. Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study.
Morimoto K; Uchino J; Yokoi T; Kijima T; Goto Y; Nakao A; Hibino M; Takeda T; Yamaguchi H; Takumi C; Takeshita M; Chihara Y; Yamada T; Hiranuma O; Morimoto Y; Iwasaku M; Kaneko Y; Yamada T; Takayama K
Oncoimmunology; 2021; 10(1):1950411. PubMed ID: 34290909
[TBL] [Abstract][Full Text] [Related]
13. Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy.
Cortellini A; Palumbo P; Porzio G; Verna L; Giordano AV; Masciocchi C; Parisi A; Cannita K; Ficorella C; Bozzetti F
Thorac Cancer; 2018 Dec; 9(12):1623-1630. PubMed ID: 30259689
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor.
Deng GM; Song HB; Du ZZ; Xue YW; Song HJ; Li YZ
World J Gastroenterol; 2024 Feb; 30(8):863-880. PubMed ID: 38516238
[TBL] [Abstract][Full Text] [Related]
15. Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study.
Rounis K; Makrakis D; Tsigkas AP; Georgiou A; Galanakis N; Papadaki C; Monastirioti A; Vamvakas L; Kalbakis K; Vardakis N; Kontogianni M; Gioulbasanis I; Mavroudis D; Agelaki S
Transl Lung Cancer Res; 2021 Aug; 10(8):3538-3549. PubMed ID: 34584855
[TBL] [Abstract][Full Text] [Related]
16. Body Composition and Clinical Outcomes in Esophageal Cancer Patients Treated with Immune Checkpoint Inhibitors.
Kosumi K; Baba Y; Hara Y; Wang H; Nomoto D; Toihata T; Ohuchi M; Harada K; Eto K; Ogawa K; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Baba H
Ann Surg Oncol; 2024 Jun; 31(6):3839-3849. PubMed ID: 38421531
[TBL] [Abstract][Full Text] [Related]
17. Impact of Pretreatment Weight Loss on Radiotherapy Utilization and Clinical Outcomes in Non-Small Cell Lung Cancer.
Alvarez CM; Aliru M; Gannavarapu BS; Song T; Gilmore LA; Olaechea S; Gomez DR; Ahn C; Infante RE; Iyengar P
Am J Clin Oncol; 2024 Feb; 47(2):49-55. PubMed ID: 38011024
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy.
Abed A; Calapre L; Lo J; Correia S; Bowyer S; Chopra A; Watson M; Khattak MA; Millward M; Gray ES
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33229510
[TBL] [Abstract][Full Text] [Related]
19. Cachexia and Sarcopenia in Oligometastatic Non-Small Cell Lung Cancer: Making a Potential Curable Disease Incurable?
Bartolomeo V; Jongbloed M; van de Worp WRPH; Langen R; Degens J; Hendriks LEL; de Ruysscher DKM
Cancers (Basel); 2024 Jan; 16(1):. PubMed ID: 38201657
[TBL] [Abstract][Full Text] [Related]
20. Influence of cachexia on immunotherapy efficacy and prognosis for malignant tumors of the digestive system.
Tao Z; Chen Z; Gao Y; Quan M
Cancer Rep (Hoboken); 2024 May; 7(5):e2100. PubMed ID: 38775250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
